Methods and compositions for treating hiv-associated diarrhoea

FIELD: medicine.

SUBSTANCE: present group of inventions relates to virology and gastroenterology, and concerns treating HIV-associated diarrhoea. Crofelemer is administered in a daily dose of 250-1,000 mg.

EFFECT: this provides effective treatment of diarrhoea in given group of patients, as well as reduced side effects due to use preparation in low doses.

27 cl, 23 tbl, 3 dwg, 10 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to novel compounds of formula I, possessing ability of binding with delta-opioid receptors. In formula R1 is selected from the group, consisting of i) phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxyl, di(C1-4alkyl), aminocarbonyl, chlorine and fluorine, in such a way that only one di(C1-4alkyl)aminocarbonyl is present; ii) naphthyl; iii) pyridinyl, optionally substituted with one substituent, selected from the group, consisting of C1-4alkyl, C1-4alcoxy, C1-4alkylthio, hydroxy, fluorine, chlorine and cyano; iv) pyrimidin-5-yl; v) furanyl; vi) thienyl; vii) 5-oxo-4,5-dihydro-[1,2,4]oxodiazol-3-yl; and viii) di(C1-2alkyl)aminocarbonyl; Y represents ethyl, vinyl or bond; or Y represents O, when R1 represents optionally substituted phenyl, where substituent represents C1-4alcoxy; R2 represents phenyl, optionally substituted with one-two substituents, independently selected from the group, consisting of C1-4alkyl, C1-4alcoxy, fluorine, chlorine and cyano, trifluoromethoxy and hydroxy; or R2 represents phenyl, substituted with one aminocarbonyl, di(C1-4alkyl)aminocarbonyl, C1-4alcoxycarbonyl or carboxysubstituent; R3 is selected from the group, consisting of i) 3-aminocyclohexyl; ii) 4-aminocyclohexyl; iii) piperidin-3-yl; iv) piperidin-4-yl; v) pyrrolodin-2-yl-methyl, in which pyrrolodin-2-yl is optionally substituted by 3-rd or 4-th position with one or two fluorine-substituents; vi) azetidin-3-yl; vii) 2-(N-methylamino)ethyl; viii) 3-hydroxy-2-aminopropyl; ix) piperidin-3-yl-methyl; x) 1-azabicyclo[2.2.2]octan-3-yl; and xi) 8-azabicyclo[3.2.1]octan-3-yl; or R3 together with Ra and nitrogen atom, which they both are bound to, form piperazinyl, optionally substituted with 4-C1-4alkyl; Ra represents hydrogen, 2-(N-methylamino)ethyl or C1-2alkyl, optionally substituted with azetidin-3-yl.

EFFECT: compounds can be used in treatment of pain in the range from medium to strong, caused by diseases or conditions, such as osteoarthritis, migraine, burn, fibromyalgia, cystitis, rhenite, neuropathic pain, idiopathic neuralgia, toothache, etc.

21 cl, 4 tbl, 26 ex

FIELD: veterinary medicine.

SUBSTANCE: agent for prevention of gastrointestinal diseases in calves with diarrhea syndrome comprises wt % silver nitrate 0.01-0.5, levamisole base 3.0-8.0, ascorbic acid 1.0-12.0 and water for injection - the rest.

EFFECT: antibacterial, immunomodulatory effect, anti-stress, antioxidant effect, and increase in effectiveness of prevention of gastrointestinal diseases in calves with diarrhea syndrome.

10 tbl, 6 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises giving to calves to drink the tincture of the combination herbal medicinal product - the grass of St. John's wort, meadowsweet, common yarrow, common nettle, rhizome of leather bergenia, root and rhizome of marsh cinquefoil, Scotch pine needles. At that the tincture fermented with microorganisms "EM Kurung" is used. The tincture is prepared by mixing 200 ml the tincture of the combination herbal medicinal product with 40 ml of the finished product "EM Kurung" and maintaining at the temperature of 18-20°C during the day, followed by filtration. EM-preparation "Baikal EM 1" is given to dry cows for 30 days prior to calving as a single dose in a dose of 30 ml/head. Mixoferon, sedimin and nitamin are additionally prescribed to new-born calves according to the following schedule: from the second feeding the tincture of the combination herbal medicinal product is watered with colostrum, fermented with microorganisms of EM-preparation "EM Kurung" at a dose of 150 ml/head dualfold for 10 days. On the 1, 2 and 8 day of life, mixoferon is injected intramuscularly at a dose of 9 ml/head. On the 1 and 8 day of life - nitamin and sedimin at a dose of 4 ml/head.

EFFECT: use of the claimed method enables to increase the immunobiological reactivity, energy of growth, provides prevention of gastrointestinal diseases of new-born calves.

4 tbl, 3 ex

FIELD: packaging industry.

SUBSTANCE: present invention relates to packaging products sensitive to moisture. The probiotic product comprises lyophilised lactic acid bacteria mixed with anhydrous powder for solution for oral rehydration. At that the lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration are packaged in foil with a desiccant integrated into the foil. Also the method of long-term storage of viable lyophilised probiotic lactic acid bacteria is provided. The method comprises providing the anhydrous powder for solution for oral rehydration; mixing lyophilised lactic acid bacteria with anhydrous powder for solution for oral rehydration; packing the mixed lyophilised lactic acid bacteria and the anhydrous powder for solution for oral rehydration in the package comprising the chemical desiccant material inserted into a layer of foil; and sealing the package.

EFFECT: invention enables to extend the shelf life of the probiotic product.

13 cl, 1 dwg, 1 tbl, 4 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of short-chain fatty acids, in particular derivatives of butyric acid, having physicochemical characteristics suitable for an easy oral administration, being devoid of the unpleasant organoleptic properties that characterise butyrate.

EFFECT: novel compounds have an easily weighable form, are stable to acids and alkalis and are capable of releasing the acid in the small and large intestines continuously over a long time.

7 cl, 5 dwg, 15 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: pharmaceutical composition for the reduction of a primary radiation response and an early transient incapacity containing ondansetron and gastrozepin in mass ratio 1-12:2-15; the composition is used as an injectable dosage form.

EFFECT: what is developed is the new composition.

3 cl, 3 tbl, 2 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly to using probiotics in the manufacture of a drug or a therapeutic nutritional composition for long-term prevention of diarrhea in infants. Using the probiotic Lactobacillus rhamnosus ATCC 53103 or Lactobacillus rhamnosus CGMCC 1.3724, and the probiotic Bifidobacterium longum ATCC BAA-999 in the manufacture of a drug or a therapeutic nutritional composition to be introduced into an infant for at least three months for the purpose of long-term prevention of diarrhoea, wherein the probiotic is introduced into a breastfeeding infant from a nursing mother.

EFFECT: using the above probiotic strains from the nursing mother is effective for the purpose of long-term prevention of diarrhoea in infants.

6 cl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to veterinary science, and aims at treating viral diseases in animals. What is declared is a composition for treating viral diseases in animals, containing two subtypes of vertebrate recombinant interferon mixed in equal molar proportions.

EFFECT: use of the declared composition enables ensuring the substantial increase of the therapeutic effect of recombinant interferons and minimising the potential adverse effects associated with their use.

4 ex

FIELD: medicine.

SUBSTANCE: what is presented is the use of the strain Lactobacillus johnsonii in preparing a probiotic composition for prevention of postoperative abdominal and pelvic infections caused by pelvic liquid accumulation, anastomosis leakage, or caused by bacterial translocation.

EFFECT: colonic L Johnsonii Lai colonisation in the patients underwent colectomy for colorectal adenocarcinoma.

11 cl, 1 dwg, 1 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention relates to feeding of newborn babies delivered by Caesarian section. Claimed is change of composition which contains long-chain polyunsaturated fatty acid and, at least, one substance, selected from group, consisting of (a) nucleotide and (b) nucleotide precursor, selected from group consisting of nucleotides, purine bases, pyridine bases, ribose and deoxyribose for obtaining composition for introduction to newborn baby delivered by Caesarian section, for treatment and/or prevention of infection, diarrhea, intestine phlegmon, allergy, atopic eczema, asthma, allergic rhinitis and/or allergic conjunctivitis. Composition can also be used to improve intestinal maturation, reduction of intestinal permeability and/or for treatment of disorders associated with intestinal barrier, in newborn baby delivered by Caesarian section. Introduced to newborn baby composition is not human breast milk.

EFFECT: invention makes it possible to improve intestinal flora of newborn babies, delivered by Caesarian section.

12 cl, 5 tbl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely represents composition, which contains mixture of particles of hydrophobic silicon dioxide aerogel, which have specific area of surface per weight unit (Sw) in range from 500 to 1500 m2/g and size, expressed in form of volume mean diameter (D[0.5]), in range from 1 to 1500 mcm, and at least one first linear silicone oil, which has viscosity higher than 50 mm2/s, and at least second and third linear silicone oils, and each of them has viscosity lower than or equal 50 mm2/s.

EFFECT: mixture of particles of silicon dioxide aerogel and linear oils provides possibility of obtaining compositions, which provide comfort and smoothness of skin after application and have dullness and "soft focus"-adding properties.

23 cl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to an antiseptic pharmaceutical composition applicable for oral hygiene and treatment of microbial oral diseases, to a method for producing and using it. The composition contains from 0.05 to 0.3 wt % of hydrogen peroxide or its equivalent amount in the form of carbamide peroxide, from 0.001 to 0.03 wt % of eugenol, from 0.001 to 0.01 wt % of camphor, from 0.001 to 0.5 wt % of a salt of zinc or other heavy metals, such as silver, mercury, copper or a mixture thereof; from 1 to 1.2 wt % of sodium fluoride; from 2% to 7 wt % of xylitol, from 0.002 to 0.05 wt % of cetylpyridinium chloride and excipients in an amount sufficient to reduce the composition to 100%. The composition possesses a wide spectrum of action. What is also presented is a method for producing the composition and using it for producing a therapeutic agent effective for odour elimination, suppression and relief of an oral inflammation, dental tartar inhibition; for treating oral diseases; for rinsing and treating orthodontic damages; for preventing oral diseases during orthodontic treatment after oral operations and in the patients using fixed and temporary dentures; for relieving, treating or preventing oral diseases in different categories of patients, such as the patients receiving radiation therapy or chemotherapy, hospital patients and terminally ill patients, patients suffering from eating disorders, endocrine, haematological, cardiovascular and psychosomatic disorders, and besides physically or mentally deprived patients, patients with genetic or inherited changes.

EFFECT: preparing the antiseptic pharmaceutical composition.

22 cl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, namely to a method for preparing a medicinal product possessing choleretic activity. The medicinal product possessing choleretic activity and prepared by extracting an elevated part of Lomatogonium carinthiacum in 96% ethanol twice at room temperature, them in 40% ethanol with an extractant added in an amount equal to a discharged one, twice; the filtered aqueous-alcoholic extracts are combined; the extraction cake is extracted in purified water; the aqueous extract is filtered; the aqueous residues of the aqueous-alcoholic extracts are combined with the aqueous extract, concentrated, dried in a vacuum drying cabinet to produce the dry extract in the certain environment.

EFFECT: medicinal product prepared as described above possesses the evident choleretic activity.

11 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: group of inventions relates to medicine and is intended for oral cavity care. Compositions contain non-dialysable material of cranberry extract, in which non-dialysable material of cranberry extract is present in quantity, effective for inhibiting co-aggregation of oral cavity bacteria and/or inhibiting bacterial growth.

EFFECT: group of inventions makes it possible to increase efficiency of oral cavity care due to inhibition of bacterial growth and co-aggregation of bacteria.

15 cl, 5 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

Black adler syrup // 2557929

FIELD: medicine.

SUBSTANCE: black adler syrup having laxative action, characterised by the fact that it is produced by preparing black adler tea by boiling the raw material with purified water; the tea is further mixed with refined sugar; the mixture is heated until the sugar is dissolved completely and brought to boil twice with skimming as often as it may be required; the prepared syrup is filtered through gauze in the certain environment.

EFFECT: syrup is high in anthracene derivatives and possesses the pronounced laxative action.

2 dwg, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine and cosmetology, namely to deep cosmetic products, and can be used for normalising physiological functions of skin and eliminating endogenous or exogenous defects. The invention represents a cosmetic product for fast skin repair containing superoxide dismutase, dexpanthenol, succinic acid, trolox and L-arginine. The product is applied on the skin for 20 minutes with using a material holding the agent and feeding it to the skin over the period of exposure.

EFFECT: cosmetic product enables extending the range of products for improving the skin state, reducing the risk of lower controllability of the effect, and a probability of allergic and inflammatory reactions.

3 cl, 10 ex

FIELD: medicine.

SUBSTANCE: using a polyphenolic complex produced by extracting milled ash berry in 40% ethanol, condensing the alcohol-water extract, adding 95% ethanol, centrifuging the residue, filtering and condensing the supernatant in the certain environment, as an agent possessing anti-inflammatory action.

EFFECT: polyphenolic complex possesses pronounced anti-inflammatory action.

1 dwg, 9 tbl, 7 ex

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical composition, containing compound of formula or for prevention or treatment of diseases, associated with oxidative stress, selected from group, consisting of MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke episodes), MERRF syndrome (myoclonic epilepsy with ragged red fibres) or Kearns-Sayre syndrome, arrhythmia, cardioplegia or myocardium infarction. in formula (1) na stands for 1 or 2, Aa represents 5-membered heteroaryl or heterocycle, each of which has 2 heteroatoms, selected from N, O and S, Rla represents R5a-Xa-Ba-X′a-, Ba represents direct bond, Xa and X′a independently on each other represent direct bond or -OC(O)-, R5a represents hydrogen or 6-9-membered monocyclic or condensed cyclic heterocycle or heteroaryl, each of which has from 1 to 3 heteroatoms, selected from N, O and S, and is optionally substituted with oxo or C1-C6-alkyl, R2a represents -(CR8aR9a)pa-Ya-R7a, pa stands for number from 0 or 1, Ya represents direct bond or -O-, R7a represents hydrogen or phenyl, R3a, R8a, R9a, R10a represent hydrogen, R4a represents -(CH2)pa-Da-R10a-, Da represents C5-cycloalkyl or 6-membered heterocycle, which has 1 heteroatom, selected from N, S and O. Radical values for formula (2) are give in invention formula.

EFFECT: obtaining compositions for prevention or treatment of diseases, associated with oxidative stress.

19 dwg, 5 tbl, 3 ex

FIELD: medicine, oncology, amino acids.

SUBSTANCE: invention relates, in particular, to the development of an antitumor preparation based on natural substances. Invention relates to an amino acid preparation comprising at least one modified essential amino acid obtained by treatment of amino acid by ultraviolet radiation (UV) at wavelength 250-350 nm for 12-80 h at temperature 15-30oC or with ozone at temperature 15-25oC. The modified amino acid has no toxicity for health cells. Also, invention relates to a method for preparing such preparation. Invention provides the development of an antitumor preparation based on modified amino acids and expanded assortment of antitumor preparations being without cytotoxicity for normal cells.

EFFECT: valuable medicinal antitumor properties of preparation.

8 cl, 4 tbl, 2 dwg, 4 ex

Up!